Welch & Forbes’s Haemonetics HAE Stock Holding History

Welch & Forbes’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,000	Closed	-$230K	–	340
2019 Q4	$230K	Hold	2,000	–	–	0.01%	334
2019 Q3	$252K	Hold	2,000	–	–	0.01%	326
2019 Q2	$241K	Buy	+2,000	New	+$197K	0.01%	319
2019 Q1	–	Sell	-2,000	Closed	-$200K	–	349
2018 Q4	$200K	Hold	2,000	–	–	0.01%	327
2018 Q3	$229K	Buy	+2,000	New	+$207K	0.01%	336

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Welch & Forbes's HAE Position: Q1 2020 in Review

Welch & Forbes sold out of Haemonetics (HAE) in Q1 2020, closing a stake of 2,000 shares — an estimated $230K sold.

Welch & Forbes first reported a position in HAE in Q3 2018 and held it in 5 quarters. The position peaked at $252K in Q3 2019. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

Welch & Forbes reported no remaining Haemonetics position as of Q1 2020 after selling out during the quarter.
Welch & Forbes sold 2,000 Haemonetics shares in Q1 2020, an estimated $230K.
Welch & Forbes first reported a position in Haemonetics in Q3 2018 and held it in 5 quarters.
Welch & Forbes's Haemonetics position peaked at $252K in Q3 2019.
269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Welch & Forbes's 13F filing for Q1 2020, filed 17 Apr 2020.